Late-breaking oral presentation on the positive primary outcomes of aderamastat, a first-in-class, oral MMP-12 inhibitor in a Phase 2 Phase 2 proof-of-concept allergic asthma study, supporting potential novel anti-inflammatory mechanism for respiratory diseases. TAIPEI, Sept. 12, 2023…